Stockwinners Market Radar for August 15, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:50 EDT Medical Properties Trust raises quarterly dividend to 26c per share from 25c - The dividend is payable on October 10, 2019 to stockholders of record on September 12, 2019.

18:28 EDT Nvidia CEO says Super GeForce RTX is off to a 'super start'

18:05 EDT ZTO Express backs FY19 parcel volume outlook of 11.51B-11.93B, up 35%-40% - Backs FY19 net income growth view of 14.3%-23.8% at RMB4.8B-RMB5.2B.

17:50 EDT Nvidia CFO sees Q3 tax rate at 9%-11% and Capex at $100M-$120M.

17:41 EDT Nvidia CFO says pleased with sequential revenue growth in Gaming in Q2 - Says unveiled 3 new GPUs in July, which deliver a performance boost of up to 26% from initial Turing processor. Says excitement around new gaming titles like Cyberpunk 2077 is "tremendous". Says Laptops continues to be a growth driver business. Says console business to remain strong in Q3 before a seasonal slowdown in Q4. Says Hyperscale portion of Data Center segment still impacted by weak spending. Comments taken from Q2 earnings conference call.

17:23 EDT Honeywell awarded $110.87M Army contract modification - Honeywell was awarded an $110.87M modification to a contract for total integrated engine revitalization, or TIGER, hardware to meet the Anniston Army Depot production of the advanced gas turbine 1500 engine for the Abrams tanks and TIGER field repair site requirements. Work will be performed in Phoenix, Arizona, with an estimated completion date of February 22, 2022. FY19 other procurement, Army funds in the amount of $110.87M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

17:03 EDT General Electric CEO buys 252.2K shares of common stock - In a regulatory filing, General Electric disclosed that its CEO Lawrence Culp bought 252.2K shares of common stock on August 15th. The total transaction size was $2.0M.

16:59 EDT Casi Pharmaceuticals CEO buys 160K shares of common stock - In a regulatory filing, Casi Pharmaceuticals disclosed that its CEO Wei-Wu He bought 160K shares of common stock on August 14th. The total transaction size was $507K.

16:54 EDT Alexandria Real Estate VP John Cunningham sells over $860K in company stock - Alexandria Real Estate VP John Cunningham disclosed in a filing that he had sold 6,000 shares of company stock at an average price of $144 per share on August 13. The total transaction value of the sale was $864,000.

16:43 EDT Hess Corp. SVP Turner sells 11.3K shares of common stock - In a regulatory filing, Hess Corp disclosed that its Senior Vice President Michael Turner sold 11.3K shares of common stock on August 13th. The total transaction size was $695K.

16:33 EDT Air Lease delivers first of 8 Boeing 787-10 aircraft to Vietnam Airlines - Air Lease (AL) announced the delivery of one new Boeing (BA) 787-10 aircraft on long-term lease to Vietnam Airlines. Featuring GEnx-1B74/75 engines, this Dreamliner aircraft is the first of eight 787-10s confirmed to deliver to Vietnam Airlines through 2021 from Air Lease order book with Boeing.

16:27 EDT ViewRay COO Shahriar Matin buys 60K shares of company stock - ViewRay COO Shahriar Matin disclosed in a filing that he had purchased 60,000 shares of company stock at an average price of $4.02 per share on August 14. The transaction value of the purchase was $241,200.

16:25 EDT Nvidia jumps 6%, or $9.01, to $157.78 after Q2 tops estimates

16:24 EDT Nvidia says stock buybacks will return after Mellanox deal closes - Nvidia said it will pay its next quarterly cash dividend of 16c per share on September 20, to all shareholders of record on August 29. "The first priority of the company's cash balance is the purchase of Mellanox Technologies," it added. Nvidia notes that it will return to repurchasing its stock after the close of the Mellanox acquisition. "The regulatory approval process for this acquisition is progressing as expected, and NVIDIA continues to work toward closing the deal by the end of this calendar year," it said.

16:22 EDT Nvidia CEO says real-time ray tracing adoption has reached 'tipping point' - Jensen Huang, founder and CEO of Nvidia said in tonight's earnings release, "We achieved sequential growth across our platforms. Real-time ray tracing is the most important graphics innovation in a decade. Adoption has reached a tipping point, with NVIDIA RTX leading the way. NVIDIA accelerated computing momentum continues to build as the industry races to enable the next frontier in artificial intelligence, conversational AI, as well as autonomous systems like self-driving vehicles and delivery robots."

16:19 EDT SolarEdge names Nadav Zafrir as board co-chairman - SolarEdge announced the appointment of Mr. Nadav Zafrir as co-chairman and member of the board of directors. The appointment was approved unanimously by the board of directors and is being made to further strengthen the executive management of the company in light of the continued illness of Guy Sella, founder, Chairman and CEO of SolarEdge.

16:17 EDT Globant reports Q2 gross margin 40.2% vs. 40.1% last year - CEO Martin Migoya says: "We continue to see strong demand coming from organizations as they look to transform their businesses. Industry analysts continue to report record spending in digital and cognitive transformation in excess of $5 trillion over the years 2018 to 2021. As digitalization and high consumer expectations change, organizations need to adapt to stay relevant. We will continue to help our customers uncover ways to create more business value, making digital and cognitive transformation sustainable."

16:15 EDT FDA approves Genentech's Rozlytrek in ROS1-Positive NSCLC - Roche Group member Genentech announced that the FDA has approved Rozlytrek or entrectinib for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer, or NSCLC. The FDA has also granted accelerated approval to Rozlytrek for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. These approvals are based on results from the integrated analysis of the pivotal Phase II STARTRK-2, Phase I STARTRK-1 and Phase I ALKA-372-001 trials, and data from the Phase I/II STARTRK-NG study.

16:05 EDT Galapagos, Gilead say MAA for filgotinib being evaluated by EMA for RA treatment - Gilead Sciences (GILD) and Galapagos (GLPG) announced that the Marketing Authorization Application,MAA for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis, RA,has been validated and is now under evaluation by the European Medicines Agency, EMA. "We are excited about the validation of this application which is an important milestone in our ongoing work to improve the lives of people living with rheumatoid arthritis and other inflammatory conditions," said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences.

16:00 EDT Cubic awarded Australia army contract - Cubic announced Cubic Defence New Zealand was selected to deliver a new simulation-enabled collective training capability, to better prepare soldiers for chemical, biological, radiological or nuclear defense missions. The capability will be delivered jointly by Cubic Defence Australia and New Zealand, expanding the offering for the Australian Army Combat Training Centre based in Townsville, North Queensland. The Cubic-developed CBRND training sub-system employs simulated CBRN threats projected within a synthetic environment to live instrumented soldiers in the exercise environment.

15:41 EDT General Electric has 'plenty of liquidity,' audit committee chair says - General Electric board member Leslie Seidman is being interviewed on CNBC.

15:37 EDT Seidman says GE following accounting standards, no basis for fraud allegations - General Electric board member Leslie Seidman, an Independent Director and Chair of the Audit Committee, is being interviewed on CNBC.

14:47 EDT Central Garden & Pet authorizes new $100M stock repurchase program - Central Garden & Pet Company announced that its board of directors has authorized a new stock repurchase program. Under the new program, the company is authorized to purchase up to $100M of its common stock. In addition, the new program also authorizes the company to make supplemental purchases to minimize dilution resulting from issuances under its equity compensation plans. The company is permitted to purchase annually a number of shares equal to the number of shares of restricted stock and stock options granted in the prior fiscal year, to the extent not already repurchased, and the current fiscal year. The company recently completed the purchase of shares remaining under the board's prior stock repurchase authorization, Central Garden & Pet noted.

14:16 EDT Boeing delivers first of eight 787-10 Dreamliners to Vietnam Airlines - Boeing (BA) said it delivered the first of eight 787-10 Dreamliner airplanes to Vietnam Airlines today via lease from Air Lease Corporation (AL). Boeing said in a statement, "With the delivery to Vietnam Airlines, the 787-10 continues to expand its global presence. More than 30 of this Dreamliner model have been delivered to six operators since the airplane entered commercial service last year. Airlines are deploying the 787-10 around the world, especially in Asia as it is home to more than half of all 787-10 destinations."

13:57 EDT Revlon jumps after report say company exploring possible sale - Shares of Revlon have jumped in afternoon trading and been halted for volatility after Bloomberg's Katherine Doherty reported that the make-up maker has hired advisers from Goldman Sachs to help it explore strategic alternatives, including a possible sale. A person with knowledge of the matter said the company is exploring all options, including potential sales of parts or all of the business, though no deals have been reached at this time, reported Doherty. Near 2 pm ET, Revlon shares are up 7% to $15.55.

13:55 EDT Bronte's Hempton says Markopolos report on GE 'flat-out silly' - John Hempton of Bronte Capital called Harry Markopolos' report today on General Electric "flat-out silly" and "utterly misleading." Hempton, who admits GE is a "deeply problematic company," says its Long Term Care business, which Markopolos focuses on, is "for good reason the best performed Long Term Care business in the world." He adds, "Say what you will, GE remains the unequivocal leader in medical imaging technology and the unequivocal leader in jet engines. In both these there are very few competitors and it would be near impossible to eat into GE's lead...Harry's report is silly. The market should ignore it." Shares of General Electric are down 14%, or $1.26, to $7.76 in afternoon trading. Reference Link

13:29 EDT Disney announces 'Toy Story 4' tops $1B at global box office - Yesterday, Pixar's Toy Story 4 became The Walt Disney Studios' fifth billion dollar release for 2019, the company announced. Through August 14, the film has earned an estimated $1.0017B worldwide. It has earned $421.8M domestically to date to stand as the No. 5 animated film ever. Internationally, Toy Story 4 has earned $579.9M with debuts still to come in Germany and across Scandinavia, Disney noted.

13:03 EDT Insys treatment of childhood absence epilepsy granted orphan designation - The FDA granted orphan designation to Insys development company's treatment of childhood absence epilepsy, according to a post to the agency's website. Reference Link

12:38 EDT CommScope wins favorable ruling against Dali Wireless patent - CommScope announced that it received a favorable final decision from the Patent Trial and Appeal Board against Dali Wireless. In its final decision, the PTAB found all patent claims of U.S. Patent No. 9,531,473 being asserted by Dali Wireless in co-pending litigation are unpatentable. The PTAB ruled that each of claims 6-21 were invalid in view of the prior art submitted by CommScope. "We are very pleased with the decision finding these claims unpatentable," said Matt Melester, senior vice president, Technology Strategy for CommScope. "CommScope's investment to develop more efficient solutions in this field of digital distributed antenna systems goes back many years, resulting in prior patents that predate Dali Wireless's more recent attempts to enter this market." The PTAB's ruling follows a favorable ruling by the Northern District of Texas jury in June validating CommScope's five patents relating to digital distributed antenna systems. Further, due to the jury's finding that Dali willfully infringed each of CommScope's five patents, CommScope will file motions for enhanced damages and attorney fees. In that same litigation, Dali Wireless had included counterclaims in the Northern District of Texas action that relied on the patent claims which the PTAB has now found to be invalid.

12:07 EDT Sintx Technologies spikes 126% after Nasdaq compliance, quarterly earnings - OEM ceramics company Sintx Technologies, announced earlier, its financial results for the three and six months ended June 30 and that it received notice from Nasdaq Regulation that it is now compliant with the minimum bid price requirement for continued listing on the Nasdaq Stock Market. SINTX reported revenue of $0.2M for the three months ended June 30, and $0.1M for the three months ended March 31. GAAP basic net loss from continuing operations for the three months ended June 30, 2019, was 78c per share, compared to a basic net loss from continuing operations of $11.19 per share for the three months ended June 30, 2018. For the six months ended June 30, 2019, the Company reported GAAP basic net loss from continuing operations of $2.84 per share, compared to a basic net loss from continuing operations of $36.66 per share for the six months ended June 30, 2018. The company's cash and cash equivalents were $3.2M and as of June 30, a decrease of $2.2M from December 31, 2018. Shares of Sintx Technologies are up 126% or $2.23 to $4.00 per share in midday trading on Thursday.

12:00 EDT Tapestry falls -21.1% - Tapestry is down -21.1%, or -$5.28 to $19.72.

11:33 EDT CACI says in communication with IRS to resolve 'misunderstanding'

11:13 EDT Kraft, Mondelez to pay $16M in wheat manipulation case, CFTC says - The U.S. Commodity Futures Trading Commission announced that it obtained a $16M penalty and injunction pursuant to a federal court's entry of a consent order against defendants Kraft Foods Group, Inc. (KHC) and Mondelez Global LLC (MDLZ). The order, entered on August 14, 2019 by the Honorable Judge John Robert Blakey of the U.S. District Court for the Northern District of Illinois, resolves the CFTC's complaint alleging, among other things, manipulation of the wheat market. The $16M penalty is approximately three times defendants' alleged gain. The order also enjoins Kraft and Mondelez from engaging in future violations of the manipulation, wash trade, and position limit provisions of the Commodity Exchange Act and CFTC regulations charged in the complaint.

10:44 EDT Markopolos says GE 'a bankruptcy waiting to happen' - Harry Markopolos, who earlier today released a report accusing General Electric of accounting fraud, said he thinks GE is "cash poor" and "they are a bankruptcy waiting to happen." Markopolos continues to be interviewed on CNBC.

10:37 EDT Markopolos says didn't speak to GE because didn't want company 'cover up' - Harry Markopolos, who earlier today released a report accusing General Electric of accounting fraud, is being interviewed on CNBC.

10:00 EDT Vipshop rises 18.4% - Vipshop is up 18.4%, or $1.15 to $7.41.

09:54 EDT SS&C names Eamonn Greaves as Global Head of Sales - SS&C Technologies announced earlier the appointment of Eamonn Greaves to Global Head of Sales. Rob Stone will succeed Eamonn as Head of Alternative Assets Sales in North America. Eamonn reports to Rahul Kanwar, President and Chief Operating Officer, and Rob will report to Eamonn.

09:47 EDT Vipshop rises 15.0% - Vipshop is up 15.0%, or 94c to $7.20.

09:33 EDT PAVmed completes clinical safety study procedures for CarpX 510 resubmission - PAVmed announced that all 20 patients of its first-in-human 510(k) clinical safety study underwent successful CarpX procedures. The study is being conducted to support PAVmed's planned 510(k) re-submission to the U.S. FDA seeking marketing clearance of its CarpX minimally invasive carpal tunnel release device. "We are excited to have achieved this critical milestone," said Lishan Aklog, M.D., PAVmed's Chairman and CEO. "Our success with this study brings us one step closer to fulfilling our mission to transform how carpal tunnel syndrome is treated for millions of people worldwide, representing a billion-dollar market opportunity in the U.S. alone. CarpX performed flawlessly as a precision cutting device in these 20 consecutive patients. Using CarpX, surgeons were able to replicate the outstanding results of our pre-clinical testing and achieve the same anatomic results as traditional open surgery - complete and precise cutting of the transverse carpal ligament - using a minimally invasive approach." As per the protocol, patients are undergoing post-operative clinical follow-up at two weeks and 90 days. All of the patients who have completed their follow-up have passed the study's specified primary safety endpoint and, based on clinical observations, it is expected that all of the remaining patients will as well. PAVmed will resubmit the CarpX 510(k) application incorporating the clinical safety and effectiveness data from the study once 90-day follow-up is completed in all 20 patients.

09:17 EDT Tapestry sees low single-digit SSS growth at Coach in FY20 - Sees low to mid single-digit sales growth at Kate spade in FY20. Expects "solid" sales growth at Stuart Weitzman in FY20.

09:16 EDT J.C. Penney says 'got off to a slow start' in Q2

09:13 EDT Tapestry sees low single-digit SSS growth at Coach in Q1 - Sees Q1 Kate Spade SSS down at a high teens rate, based on current traffic trends. Sees operating loss for Stuart Weitzman in Q1.

09:09 EDT J.C. Penney says guidance doesn't include fourth tranche of tariffs

09:07 EDT Salem Media to sell nine AM stations, four FM translators for $8.73M - Relevant Radio has entered into an agreement with Salem Media to purchase nine AM stations and four FM translators in eight markets. Salem Media has agreed to sell stations to Relevant Radio in Boston, Atlanta, Houston, Dallas, San Antonio, St. Louis, Denver and Youngstown for $8.73M. This transaction, combined with purchases earlier this year of Salem stations in Washington, D.C., Miami, and Tampa, will allow Relevant Radio to expand its reach by an additional 60,000,000 persons. In total, Relevant Radio is purchasing 14 AM stations and 7 FM translators from Salem for $17,7M.

09:05 EDT Akers Biosciences says evaluation of strategic alternatives 'remains underway' - Akers Biosciences reported its financial results for the three and six months ended June 30, 2019. At June 30, 2019, Akers Bio had cash, restricted cash and marketable securities of $4.39 million. The Board of Directors' process remains underway to evaluate strategic alternatives to maximize shareholder value. The Board has been and will continue to consider a range of potential strategic alternatives including, but not limited to, business combinations in alternative sectors including cannabis and hemp related industries that comply with NASDAQ's listing requirements.

09:04 EDT Adtalem Global Education medical schools expand partnership with Mount Sinai - Adtalem Global Education medical schools, American University of the Caribbean School of Medicine and Ross University School of Medicine, have expanded a clinical partnership agreement with Mount Sinai Hospital in Chicago. "Mount Sinai Hospital is delighted to have this opportunity to provide clinical rotations for more RUSM students and to serve as a clinical site for AUC students. We greatly value our partnership with both of these excellent schools and with Adtalem Global Education," said Mira Iliescu, M.D., chief medical officer for Sinai Health System and chairman of the Department of Medicine at Mount Sinai Hospital.

08:57 EDT Madoff whistleblower Markopolos launches 'GEfraud.com' website - Harry Markopolos, the accounting expert who raised red flags about Bernie Madoff's Ponzi scheme, released his report on the accounting of General Electric on website called "GEfraud.com," claiming on the front page of the new site that GE is "a bigger fraud than Enron." In an interview with The Wall Street Journal ahead of the launch of the website, Markopolos said his group found GE's insurance unit will need to bolster its reserves by $18.5B in cash. He also faulted the way the company is accounting for its oil-and-gas business. Before the report was published, a GE spokeswoman told the Journal: "GE stands behind its financials. We operate to the highest level of integrity in our financial reporting and we have clearly laid out our financial obligations in great detail. While we can't comment on the detailed content of a report that we haven't seen, the allegations we have heard are entirely false and misleading." Shares of GE are off their lows of earlier in the pre-market session, but remain down 3.5% at $8.71. Reference Link

08:43 EDT Sigma Labs CEO says outlook is 'optimistic' - Sigma Labs has released a letter to its shareholders from John Rice, Chairman and CEO. The letter read in part, "The purpose of this letter is to brief you on Sigma Labs' 2019 operational milestones as we cross over the half-way point for the year. In conjunction with a return to quarterly financial and operational updates, I wanted to provide our loyal shareholders with my perspective from the CEO post on the company's four main principal areas in 2019. It's important to note that the final phase of foundation building is now behind us and the stage is set for commercial execution and financial performance. Now let's discuss why all of us at Sigma Labs are excited about 2019 and beyond. Sigma released Version 4.0 of its principal product, PrintRite3D, in November 2018, and Version 5.0 in May 2019... Basically, our PrintRite3D technology solution is being third-party validated and we have no direct competition in delivering actionable in process data as we strive to play a critically necessary role in ensuring quality in industrial additive manufacturing of metal parts... As announced last winter, Sigma had initiated a Rapid Test and Evaluation program to attract customers with a 'drive before you buy' proposition. We quickly discovered the word Rapid was unrealistic because of logistical delays due to clearing machine time for testing and project support personnel. We also made peace with the fact that, since PrintRite3D reveals a precision and depth of quality images and data not previously seen or understood by the customers, RTEs lead to customer requests to extend the scope and issue investigation. That adds time to the process, too. The causes of this absence of rapidness appear to us to improve the prospect for program sales, but of course the reality of slow speed is exasperating. Importantly, so far we have no negative performance issues in the RTE test results!...At this writing, of our two most advanced RTEs in process, looking out over the next 60-120 days, one states an expectation to add a second PrintRite3D installation, and the other to enter the phase two evaluation. ..The company's OEM licensing strategy and negotiations are very important to securing our principal go-to-market goal to have PrintRite3D deployed into the growing marketplace direct from the factory and pre-mounted on the new machines...As mentioned earlier in late July, we announced that Sigma had been selected by Airbus for a Rapid Test and Evaluation program. While this was a very, very important milestone, the impact from a stock perspective was minimized due to a simultaneous capital raise via a shelf offering with Aegis Capital as underwriter. A combination of proper governance and our CFO's strict cash management, we had implemented a plan in the spring of 2019 to ensure the company had ample capital to fund our commercial path in 2019. While timing and market conditions are never perfect, we felt it was the prudent and necessary time to accomplish this goal and provide the company with a stable financial runway. Looking back at the recent stock market volatility this week, we are very confident we made the right decision...In conclusion, our outlook is optimistic because:Our balance sheet is now fortified; Our IP portfolio has a virtual moat around the entire quality control industry for additive manufacturing; Our total addressable market or TAM is in the multi-billions, growing and global; Our RTE program is growing with some of the largest global companies; Machine OEM partnerships are now happening; Software partnerships are now developing with leading providers of additive manufacturing and 3D printing solutions; and Commercial orders are now on the horizon for Q3 2019 with a clear line of sight to breakeven operations by early 2020."

08:40 EDT Tapestry 'not pursuing strategic acquisitions' in FY20 - Tapestry management noted they have revised their FY20 capital allocation policies and the company is not pursuing strategic acquisitions in FY20. The company is focused on delivering share repurchases of $300M of common stock and maintaining the dividend. The company is focused on leveraging investments in their platform. Comments provided during Q4 earnings conference call.

08:38 EDT RGS Energy joins Builder Partnerships network - RGS Energy announced that it has joined Builder Partnerships network to offer POWERHOUSE to their over 1,400 builder members. Builder Partnerships network is a unique networking organization that supports leading regional builders and manufacturers as they compete and thrive in today's competitive environment. They help their members generate superior returns, establish strategic relationships and enhance management practices.

08:36 EDT J.C. Penney CEO says has 'every intention' of increasing share price to above $1

08:35 EDT J.C. Penney CEO says 'confident' company will return to sustainable growth - Comments taken from Q2 earnings conference call.

08:34 EDT Cellectar Biosciences appoints Dov Elefant as CFO - Cellectar Biosciences (CLRB) announced the appointment of Dov Elefant as its CFO effective as of September 10, 2019. Elefant joins Cellectar after having served as CFO at several companies, most recently at Akari Therapeutics (AKTX).

08:32 EDT Daseke announces CEO Don Daseke to retire - Daseke announced that Don Daseke will retire from his roles as CEO and Chairman of the Board effective immediately, but that he will continue as a member of the Board with the title, Chairman Emeritus. Daseke's Board of Directors has appointed Chris Easter, its COO, as Interim CEO, effective immediately. Mr. Daseke will work with Mr. Easter in an advisory capacity to help ensure a smooth transition while the Board conducts a search for a permanent CEO. The Company also announced that the Board of Directors has appointed Brian Bonner as Executive Chairman effective immediately.

08:22 EDT Just Energy appoints Walter Higgins to board of directors - Just Energy Group Inc. (JE) announced Walter Higgins III has been appointed to Just Energy's Board of Directors, as an independent director. Higgins is currently the Chairman of the Board of South Jersey Industries Inc. (SJI).

08:17 EDT Micron commences volume production of 1z nanometer DRAM process node - Micron Technology announced advancements in DRAM scaling, making Micron the first memory company to begin mass production of 16Gb DDR4 products using 1z nm process technology. Micron's 1z nm 16Gb DDR4 product delivers substantially higher bit density, as well as significant performance enhancements and lower cost compared to the previous generation 1Y nm node. It also reinforces Micron's continued progress in delivering improvements in relative performance and power consumption for compute DRAM, mobile DRAM and graphics DRAM product lines. The optimized balance between power and performance will be a key differentiator for applications including, among others, artificial intelligence, autonomous vehicles, 5G, mobile devices, graphics, gaming, network infrastructure and servers.Micron initiated the transition to 1z nm with mass production of its 16Gb DDR4 memory solution. Production using the smaller node delivers several benefits, including an approximately 40% reduction in power consumption compared to previous generations of 8Gb DDR4-based products. Micron's comprehensive portfolio of 1z nm DDR4 products targets the growing need for better performance, higher density and reduced power consumption in the modern data center. Separately, Micron is also announcing that it has begun volume shipments of the industry's highest-capacity monolithic 16Gb low-power double data rate 4X DRAM in UFS-based multichip packages. Micron's 1z nm LPDDR4X and uMCP4 address the needs of mobile device manufacturers seeking low power and smaller packages to design devices with attractive form factors and long battery life.

08:14 EDT Tabula Rasa HealthCare to provide CMR opportunities to community pharmacists - Tabula Rasa HealthCare announced a new offering of Comprehensive Medication Review opportunities to community pharmacists through the collaboration of two of its subsidiary companies, SinfoniaRx and PrescribeWellness. Community pharmacists now will have the opportunity to conduct face-to-face CMRs with their patients and receive compensation for additional clinical services. The collaboration between SRx, the largest provider of telephonic CMRs, and PW, one of the largest networks of community pharmacies, benefits patients, their pharmacists and their health plans. For patients, there is an increased access to telephonic or in-person consultations. For pharmacists, the CMRs can be quickly and accurately documented as eCare Plans within the Patient Engagement Center using PrescribeCare, as they review all of a patient's medications to help determine the efficacy of each medication prescribed. For payors, more eligible members will complete a CMR to ensure they are receiving optimized care.

08:13 EDT Super League Gaming partners with Metarama Gaming + Music Festival - Super League Gaming announced a partnership with Metarama Gaming + Music Festival to produce a "Pros vs. Joes" League of Legends tournament in Las Vegas being held October 19-20, 2019. Amateur League of Legends players nationwide will have the opportunity to compete for a chance to win a once-in-a-lifetime, all-expenses-paid trip to Las Vegas to compete on stage at the festival against teams made up of top League of Legends players.

08:11 EDT Ekso Bionics unveils EksoNR exoskeleton - Ekso Bionics Holdings unveiled EksoNR, the next generation EksoGT. EksoNR is an intuitive exoskeleton device that empowers patients recovering from stroke or other conditions to learn to walk again with a more natural gait. The device now includes new features and software enhancements to help physical therapists and patients get even more out of each rehabilitation session. EksoNR is equipped with EksoView, a new touchscreen controller that allows therapists to intuitively adapt assistance to challenge patients using real-time feedback and perform outcome measures during use. Held in the palm of a therapists' hand, EksoView provides visualization of various exercises beyond gait training, such as balancing, squatting from sit-to-stand positioning, lifting one leg, or standing in place, to actively engage patients and enhance the use of these beneficial features. EksoNR is cleared by the U.S. Federal Drug Administration for stroke and spinal cord injury rehabilitation. The device is also CE-marked and available in Europe. Ekso Bionics will begin taking orders for EksoNR immediately. Existing customers will have the option to upgrade.

08:08 EDT Briggs & Stratton to consolidate small engine production - Briggs & Stratton announced plans to consolidate production of its small vertical-shaft engines into its Poplar Bluff, Missouri facility. This consolidation will result in the closure of the company's Murray, Kentucky facility by the fall of 2020 and is intended to align production capacity with current and expected future market needs. The market for small vertical-shaft engines has been relatively stable over the last several years but has not grown for various reasons. Unlike other areas of Briggs & Stratton's business such as commercial engines and products which have seen double-digit growth, the residential walk-behind mower market, where the vast majority of these engines are used, has not rebounded to historical levels. Accordingly, the company is taking action to right-size its footprint. Impacted employees will have the opportunity to relocate to another facility. The Poplar Bluff plant will be hiring to accommodate the increased production being added to that facility, in addition to the hiring taking place within the company's commercial businesses. The company anticipates annualized pre-tax savings of $12M-$14M, with approximately $10M recognized by FY21. Total charges related to the consolidation are expected to total $30M-$35M over FY20 and FY21.

08:07 EDT RBC Bearings acquires Swiss Tool Systems for $33.9M - RBC Bearings announced the acquisition of Swiss Tool Systems AG, from Cross Equity Partners and other private owners for approximately $33.9M, to be financed through cash on hand and debt. Swiss Tool Systems has annual sales of approximately $11.3M and the company has approximately 50 employees.

08:06 EDT AMSC announces $9M wind turbine electrical control system order - AMSC announced it has received a $9M order for its 5.5 megawatt wind turbine electrical control systems from Doosan Heavy Industries & Construction Co., South Korea's premium wind turbine manufacturer. AMSC signed an agreement with Doosan in calendar year 2017 for the rights to design and exclusively supply ECS units to Doosan's 5.5-megawatt offshore wind turbine. The initial 5.5 MW systems were ordered in January 2018, and AMSC expects to complete shipments under this follow-on order by no later than fiscal year 2020.

08:04 EDT Restoration Robotics receives CE Mark approval for ARTAS iX System - Restoration Robotics announced that it received CE Mark approval for the sale of the ARTAS iX System with implantation functionality in Europe. The CE Mark approval follows the Company's receipt of ISO 13485:2016 Certification for ARTAS iX in January 2019.

07:56 EDT Engine Capital issues letter to board of Care.com - Engine Capital, a sizeable shareholder of Care.com, issued an open letter to the company's board encouraging the board to initiate a parallel process to explore strategic alternatives while searching for a new CEO and implementing various initiatives identified by Engine. The letter said, "...These discussions have led us to the conclusion that Care.com is a unique asset that is currently underearning, misunderstood by the market and significantly undervalued. The Company is the undisputed leader in a very large and fragmented market. It has the largest supply of caregivers and the largest number of families in a "winner take all" marketplace. It owns a full suite of payment products. It has a strong brand as evidenced by high net promoter scores. It also owns a valuable separate but related business with Care@Work. And yet, despite all these valuable assets, the Company has miserably failed to create any shareholder value over any relevant measurable period as shown in the below table.1 CRCM's current valuation of approximately 1x revenue represents a deep discount to the valuation of other similar online marketplaces and reflects investors' concerns regarding Care.com's business model and future prospects following the March 8, 2019 Wall Street Journal article questioning the Company's safety practices. This article and its surrounding publicity have jeopardized one of the Company's core pillars, namely, the trust in Care.com's services and in the Company's brand itself. This erosion of trust puts the long-term relationship between Care.com and its consumers at risk and creates significant uncertainty in the Company's long-term financial model. The first cracks to this financial model were visible when the Company reported its Q2 2019 results with paying families in the US consumer business declining quarter-over-quarter and traffic negatively affected by word-of-mouth. The reduced traffic generated from word-of-mouth is particularly troubling as it is one of the lowest cost customer acquisition channels. These negative trends, in addition to the increased spend in safety and cybersecurity, are anticipated to significantly detract from the attractive unit economics the Company has previously enjoyed. While we believe many of these issues are fixable, it will take time and there are significant execution risks, including the appointment of a new management team, the restoration of the trust factor and the establishment of new unit economics for the business. At the same time, the Company has significant strategic value and certain buyers may be able to pay a price that is superior to the standalone value of the Company, especially taking into account the time value of money and execution risk. We believe the Board has a fiduciary duty to immediately start a parallel process whereby it continues the search for the Company's next leadership team but at the same time explores the Company's strategic options to assess what a buyer may pay for the Company today... We firmly believe that the Company is at a crossroads and that time is of the essence for significant changes to be made given the Company's persistent underperformance. The Board has a unique window of opportunity to pursue a parallel strategic review process while working on the value enhancing initiatives described above. It is our desire to work collaboratively with the Board to improve the Company and drive shareholder value, which is why we request an opportunity to discuss these important matters further with the Board. We look forward to engaging with you and other shareholders to discuss these topics further."

07:47 EDT Alibaba CEO says still adopting conservative approach to monetization

07:46 EDT GE shares drop 5.5% to $8.53 after Madoff Whistleblower targets accounting

07:42 EDT J.C. Penney to offer selection of clothing, handbags from thredUP in 30 stores - J. C. Penney Company announced that 30 JCPenney stores will soon be offering a sought-after selection of secondhand women's clothing and handbags from thredUP, the world's largest online consignment store featuring like-new styles from leading designers and brands. As part of a Company effort to launch new customer offerings, each thredUP shop at JCPenney will be thoughtfully curated and refreshed weekly to offer continued newness and excitement for shoppers. Offering a seasonal array of resale handbags and women's fashion, the thredUP assortment will be uniquely branded in a 500-to-1,000 sq. ft. presentation in select markets starting this week.

07:35 EDT Lexaria Bioscience says has received four new patents - Lexaria Bioscience announced that four of its pending patent applications, via its wholly-owned subsidiary Poviva Corp., have now been granted. The four new patents granted are as follows: Methods for formulating orally ingestible compositions comprising lipophilic active agents as well as Food and beverage compositions infused with lipophilic active agents and methods of use thereof. The issuance of these four patents results in Lexaria's total patents granted increasing to 15 with eight granted in the US and seven granted in Australia, along with roughly 60 patent applications pending throughout the world. The granted patents cover delivery of: cannabinoids such as THC and CBD; NSAIDs such as ibuprofen; nicotine; and vitamins.

07:33 EDT Alliance Data reports July net charge-offs 5.7% - Reports July delinquency ratio 5.5% vs. 5.7% last year.

07:23 EDT Alibaba: Annual active consumers on China retail market places reached 674M - Says annual active consumers on China retail marketplaces reached 674 million, an increase of 20 million from the 12-month period ended March 31, 2019. Mobile MAUs on its China retail marketplaces reached 755 million in June 2019, an increase of 34 million over March 2019.

07:20 EDT Walmart CFO says expects currency to be continued headwind in Q3 - Based on current exchange rates, Walmart expects net sales will be negatively affected by about $500M in Q3, which is higher than anticipated at the beginning of the year.

07:18 EDT Walmart: Over 2,700 stores offer free grocery pickup - Says over 1,100 stores offer same-day grocery delivery. Says "on pace" to reach year-end goals of 1,600 same-day grocery delivery stores and 3,100 stores with grocery pickup. Says testing in-home delivery of groceries in three markets.

07:16 EDT Walmart: Exceeded goal to serve about 75% of U.S. with NextDay delivery - Says working to expand NextDay delivery further. Says expanding presence in WeChat app.

07:13 EDT CEO McMillon says Walmart represents about 2% of market for firearms today - In the company's Q1 earnings commentary, President and CEO Doug McMillon said Walmart is "thinking through the broader issues related to gun violence and things we should do to help create safer communities." McMillon said Walmart: Stopped selling handguns in every state but Alaska in the mid 90s, stopped selling military-style rifles such as the AR-15 in 2015, raised the age limit to purchase a firearm or ammunition to 21 in 2018. He said Walmart only sells a firearm after receiving a "green light" on a background check, while federal law only requires the absence of a "red light" after three business days and said "We don't sell a firearm until we receive a "green light" regardless of the time period." He added that "We videotape the point of sale for firearms, only allow certain associates to sell firearms, and secure firearms in a locking case with individual locks, among other measures." McMillon estimated that Walmart represents about 2% of the market for firearms today, which he believes places it outside at least the top three sellers in the industry, and says Walmart has about a 20% share of ammunition. "we believe there authorization of the Assault Weapons ban should be debated to determine its effectiveness in keeping weapons made for war out of the hands of mass murderers," McMillon said.

07:10 EDT Group 1 Automotive increase quarterly dividend 7.7% to 28c per share - Group 1 Automotive announced that its board of directors declared a cash dividend of 28c per share for Q2. The dividend, which represents an increase of 7.7%, or 2c per share, from Q1, will be payable on September 17 to stockholders of record as of September 3.

07:08 EDT Auris expects top-line results from Phase 1b trial of AM-201 in coming weeks - Completed enrollment in the Phase 1b trial with AM-201 in antipsychotic-induced weight gain. In early July 2019, the Company completed enrollment in the Phase 1b proof-of-concept trial with AM-201 in antipsychotic-induced weight gain and somnolence. The trial is being conducted at a single trial site in Europe and enrolled 50 healthy volunteers who received either AM-201 or placebo concomitantly with olanzapine over four weeks. The primary efficacy outcome for the study is the reduction in weight gain and the secondary outcome is the reduction in somnolence. The Company expects top-line results from the trial in the coming weeks. Based on the positive safety signals observed so far, and subject to positive trial outcomes and the receipt of the necessary approvals, the Company plans to extend the dose escalation by adding two more doses to the five doses tested so far.

07:08 EDT Phio Pharmaceuticals, Helmholtz Zentrum Munchen enter research collaboration - Phio Pharmaceuticals announced that is has entered into a research collaboration with the Helmholtz Zentrum Munchen. The agreement covers the design and development of new targets based on Phio Pharmaceuticals' proprietary self-delivering RNAi platform for use in cancer immunotherapies. This work will be performed at the Immunoanalytics Core Facility and will complement Phio Pharmaceuticals' internal research and development activities and collaborations with various other academic and industry partners.

07:06 EDT Valeritas says trial on insulin delivered by V-Go meets primary A1c endpoint - Valeritas Holdings announced that a randomized controlled trial comparing the delivery of U-100 Regular Human Insulin by V-Go versus delivery of Rapid Acting Insulin by V-Go in patients with type 2 diabetes has met the primary A1c endpoint. A planned interim analysis was reviewed by an independent Data Safety and Monitoring Committee who unanimously recommended stopping further participant screening and randomization after determining non-inferiority had been met when examining the change in A1c over the treatment period between the two arms. The DSMC concluded that the data collected after 75% of the patients had been randomized was sufficient to support the conclusion that the study had successfully achieved the study's primary endpoint. Because no untoward safety signals were seen, the investigators agreed on August 12, 2019 to end the study early. At this time the use of U-100 Regular Human Insulin with V-Go Wearable Insulin Delivery device has not been cleared by the Food and Drug Administration. A U-100 fast acting insulin should be used with V-Go. Humalog and NovoLog have been tested by Valeritas, Inc. and found to be safe for use in the V-Go Wearable Insulin Delivery device.

07:04 EDT Advanced Emissions joint venture closes on Refined Coal facility transaction - Advanced Emissions announced that Tinuum Group, a joint venture among the company's subsidiary ADA-ES, an affiliate of NexGen Resources, and an affiliate of The Goldman Sachs Group, has completed a transaction for an additional Refined Coal facility. The RC facility is located at a coal-fired power plant that has historically burned in excess of 5.5 million tons of coal per year and is royalty bearing to ADES. With this addition, Tinuum Group has 22 invested facilities in full-time operation. Advanced Emssions CEO L. Heath Sampson commented, "At the end of 2018, we outlined what we believed was a clear path to securing an additional 12 million incremental tons in 2019 from prospective tax equity investors. I'm pleased to announce today that we have met this goal ahead of our target date as Tinuum has secured a third-party investor for facility number 22, making it the third contracted refined coal facility in 2019 and fifteenth royalty bearing facility overall. The 5.5 million tons related to this closure now brings us to over 12 million annualized tons contracted during 2019 and is larger than the historical annual tonnage associated with closures in 2018 (...)".

07:03 EDT Virtus Investment increases quarterly dividend 22% to 67c per share - Virtus Investment announced that its board has declared a quarterly cash dividend on its common stock of 67c per share, a 22% increase from the previous quarterly dividend of 55c per share. This is the second consecutive year the company has increased its common stock dividend since a quarterly dividend was initiated in May 2014. The common stock dividend will be paid on November 15 to shareholders of record at the close of business on October 31.

07:00 EDT Bank of America reports July net charge-offs 2.49% vs. 2.71% last month - Reports July 30-plus day delinquencies 1.57% vs. 1.56% last month.

06:53 EDT JPMorgan reports July card charge-offs 2.21% vs. 2.30% last year - Reports July 30-plus day delinquencies 1.15% vs. 1.10% last year.

06:51 EDT Mallinckrodt's Phase 3 trial of terlipresin in HRS-1 meets primary endpoint - Mallinckrodt announced positive top-line results from its pivotal Phase 3 CONFIRM clinical study evaluating the efficacy and safety of terlipressin in 300 adults with hepatorenal syndrome type 1. The study met its primary endpoint of verified HRS-1 reversal. Verified HRS-1 reversal includes three components: renal function improvement, avoidance of dialysis and short-term survival. The company plans to present the data at an upcoming medical meeting. HRS-1 is a life-threatening, rare and acute disease characterized by complications of liver disease that lead to kidney failure. HRS-1 has a very poor prognosis, with a median survival time of less than two weeks and greater than 80% mortality within three months. At present, there are no approved drug therapies for HRS-1 in the U.S. or Canada. HRS-1 is estimated to affect between 30,000 and 40,000 patients in the U.S. annually. The company plans to submit a New Drug Application to the FDA in early 2020.

06:12 EDT Sealed Air switches audit firms in light of SEC subpoena - In a regulatory filing, Sealed Air said this week that it's audit committee dismissed Ernst & Young as the company's independent registered public accounting firm effective as of that date. "This change is being made in light of the Company's previously disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission on May 2, 2019 for documents and information relating to the process by which the Company selected its independent audit firm for the period beginning with fiscal year 2015, and relating to the independence of that audit firm. EY has reaffirmed to the Company that EY believes there has been no independence violation, and the Company has not reached a contrary conclusion. Nonetheless, the pendency of the SEC investigation, along with the Committee's dissatisfaction with information it learned about the process by which EY was selected as auditor, caused the Company to make this change now to allow for an orderly transition for the audit of the Company's fiscal 2019 consolidated financial statements and to minimize the risk of disruption that could arise in the event of an unplanned change in independent auditors at an undetermined time in the future." On August 7, 2019, the Committee approved, effective immediately, the engagement of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the company's fiscal year ending December 31, 2019.

06:02 EDT Orion Engineered CEO purchases 80,000 company shares - Orion Engineered Carbons CEO Corning Painter has purchased a total of 80,000 common shares of the Company. The shares were acquired at an average price of $12.48 per share. Painter previously purchased 36,950 common shares in November of 2018, shortly after he joined Orion as CEO and 55,000 common shares in May 2019.